Matrix metalloproteinase‑9 in pediatric rheumatic heart disease with and without heart failure

Elhewala,Ahmed A.; Sanad,Mohammed; Soliman,Alshimaa   M.; Sami,May M.; Ahmed,Alshymaa A.

doi:10.3892/br.2020.1380

Matrix metalloproteinase‑9 in pediatric rheumatic heart disease with and without heart failure

Authors:
- Ahmed A. Elhewala
- Mohammed Sanad
- Alshimaa M. Soliman
- May M. Sami
- Alshymaa A. Ahmed
View Affiliations

Affiliations: Department of Pediatrics, Faculty of Medicine, Zagazig University, Zagazig, Al Sharqia Governorate 44519, Egypt, Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Zagazig, Al Sharqia Governorate 44519, Egypt
Published online on: October 23, 2020 https://doi.org/10.3892/br.2020.1380
Article Number: 4

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In cardiovascular disorders, the myocardium may be subjected to the breakdown and remodeling of collagen by metalloproteinase‑9 (MMP‑9). We hypothesized that the serum MMP‑9 concentration may be elevated in pediatric patients with rheumatic heart disease (RHD) and heart failure (HF), and its level can be correlated with the HF severity. Thus, in the present study, we aimed to evaluate the sensitivity and accuracy of MMP‑9 to predict HF in children with RHD and to determine its effectiveness as an indicator of the degree of HF. This study included 98 consecutive children admitted to the Department of Pediatrics, Zagazig University Hospital, Al Sharqia Governorate, Egypt with newly diagnosed RHD. Their ages ranged from 8.5 to 16 years. Fifty‑eight children had RHD without HF while 40 children were complicated with HF which was diagnosed clinically and by echocardiography. A total of 44 healthy children were enrolled as a control group. MMP‑9 serum levels were estimated by enzyme‑linked immunosorbent assay. The serum MMP‑9 concentration was higher in the RHD without HF and RHD with HF groups than this level noted in the control (P<0.001). MMP‑9 was a significant predictor of HF; area under the curve (AUC)=0.85 [95% confidence interval (CI), 0.76‑0.94]. At the level of 386.9 ng/ml, MMP‑9 detected HF with a sensitivity 95% (95% CI, 83.08‑99.39), specificity 74.14% (95% CI, 60.96‑84.74), positive predictive value 71.70% (95% CI, 61.96‑79.75), negative predictive value 95.56% (95% CI, 84.67‑98.82) and accuracy 82.65% (95% CI, 73.69‑89.56). In addition, MMP‑9 showed a significant negative correlation with ejection fraction and fractional shortening (P=0.01 and P=0.02, respectively). In conclusion; MMP‑9 may be an independent sensitive marker with which to detect HF in children with RHD and it can predict the prognoses of these patients as it correlates with the severity of HF. Further studies considering MMP‑9 in the detection of ‘silent’ RHD in school aged children and asymptomatic HF in children with known RHD especially in rural areas, are highly recommended.

View Figures

View References

1	Chaturvedi V and Saxena A: Heart failure in children: Clinical aspect and management. Indian J Pediatr. 76:195–205. 2009.PubMed/NCBI View Article : Google Scholar
2	Watkins DA, Johnson CO, Colquhoun SM, Karthikeyan G, Beaton A, Bukhman G, Forouzanfar MH, Longenecker CT, Mayosi BM, Mensah GA, et al: Global, regional, and national burden of rheumatic heart disease, 1990-2015. N Engl J Med. 377:713–722. 2017.PubMed/NCBI View Article : Google Scholar
3	Dougherty S, Beaton A, Nascimento BR, Zühlke LJ, Khorsandi M and Wilson N: Prevention and control of rheumatic heart disease: Overcoming core challenges in resource-poor environments. Ann Pediatr Cardiol. 11:68–78. 2018.PubMed/NCBI View Article : Google Scholar
4	Carapetis JR, Beaton A, Cunningham MW, Guilherme L, Karthikeyan G, Mayosi BM, Sable C, Steer A, Wilson N, Wyber R and Zühlke L: Acute rheumatic fever and rheumatic heart disease. Nat Rev Dis Primers. 2(15084)2016.PubMed/NCBI View Article : Google Scholar
5	Sorour KA: Rheumatic heart disease in Egypt: Gloomy past and promising future. Egypt Heart J. 66:139–142. 2014.
6	Sarkar S, Rastogi M, Chaudhary P, Kumar R, Arora P, Sagar V, Sahni IS, Shethi S, Thakur K, Ailawadhi S, et al: Association of rheumatic fever & rheumatic heart disease with plausible early & late-stage disease markers. Indian J Med Res. 145:758–766. 2017.PubMed/NCBI View Article : Google Scholar
7	Fernandes BA, Maher KO and Deshpande SR: Cardiac biomarkers in pediatric heart disease: A state of art review. World J Cardiol. 8:719–727. 2016.PubMed/NCBI View Article : Google Scholar
8	Nadar SK and Shaikh MM: Biomarkers in routine heart failure clinical care. Card Fail Rev. 5:50–56. 2019.PubMed/NCBI View Article : Google Scholar
9	Azevedo A, Prado AF, Antonio RC, Issa JP and Gerlach RF: Matrix metalloproteinases are involved in cardiovascular diseases. Basic Clin Pharmacol Toxicol. 115:301–314. 2014.PubMed/NCBI View Article : Google Scholar
10	Radosinska J, Barancik M and Vrbjar N: Heart failure and role of circulating MMP-2 and MMP-9. Panminerva Med. 59:241–253. 2017.PubMed/NCBI View Article : Google Scholar
11	Wagner DR, Delagardelle C, Ernens I, Rouy D, Vaillant M and Beissel J: Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J Card Fail. 12:66–72. 2006.PubMed/NCBI View Article : Google Scholar
12	Reményi B, Wilson N, Steer A, Ferreira B, Kado J, Kumar K, Lawrenson J, Maguire G, Marijon E, Mirabel M, et al: World heart federation criteria for echocardiographic diagnosis of rheumatic heart disease-an evidence-based guideline. Nat Rev Cardiol. 9:297–309. 2012.PubMed/NCBI View Article : Google Scholar
13	Jayaprasad N: Heart failure in children. Heart views. 17:92–99. 2016.PubMed/NCBI View Article : Google Scholar
14	Szczygielska I, Hernik E, Kołodziejczyk B, Gazda A, Maślińska M and Gietka P: Rheumatic fever-new diagnostic criteria. Reumatologia. 56:37–41. 2018.PubMed/NCBI View Article : Google Scholar
15	Juneja A and Sharma S: Issues of sample size in sensitivity and specificity analysis with special reference to oncology. J Cancer Res Ther. 11:482–484. 2015.PubMed/NCBI View Article : Google Scholar
16	Dougherty S, Khorsandi M and Herbst P: Rheumatic heart disease screening: Current concepts and challenges. Ann Pediatr Cardiol. 10:39–49. 2017.PubMed/NCBI View Article : Google Scholar
17	Isik A, Gursul C, Peker K, Aydın M, Fırat D and Yılmaz İ: Metalloproteinases and their inhibitors in patients with inguinal hernia. World J Surg. 41:1259–1266. 2017.PubMed/NCBI View Article : Google Scholar
18	Koestenberger M, Friedberg MK, Nestaas E, Michel-Behnke I and Hansmann G: Transthoracic echocardiography in the evaluation of pediatric pulmonary hypertension and ventricular dysfunction. Pulm Circ. 6:15–29. 2016.PubMed/NCBI View Article : Google Scholar
19	Ross RD: The ross classification for heart failure in children after 25 years: A review and an age-stratified revision. Pediatr Cardiol. 33:1295–1300. 2012.PubMed/NCBI View Article : Google Scholar
20	Cimmino G, Ragni M, Cirillo P, Petrillo G, Loffredo F, Chiariello M, Gresele P, Falcinelli E and Golino P: C-reactive protein induces expression of matrix metalloproteinase-9: A possible link between inflammation and plaque rupture. Int J Cardiol. 168:981–986. 2013.PubMed/NCBI View Article : Google Scholar
21	Harfoosh AK, Elaziz AFA, Mahmoud E and Saleh A: Matrix metalloproteinase-9 as a potential biomarker for inflammatory events in acute coronary syndrome, and its relation to diabetes mellitus in these patients. Al-Azhar Assiut Med J. 13 (Suppl 1):S71–S80. 2015.
22	Zhao Y, Zhou X, Liao X and Yang Z: Expression and significance of matrix metalloproteinase-1,9, tissue inhibitor of metalloproteinase-4 and extracellular matrix metalloproteinase inducer in the myocardium of congestive heart failure in patients with rheumatic heart diseases. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 34:790–795. 2009.(In Chinese). PubMed/NCBI
23	Abou-Raya S, Naim A and Marzouk S: Cardiac matrix remodelling in congestive heart failure: The role of matrix metalloproteinases. Clin Invest Med. 27:93–100. 2004.PubMed/NCBI
24	Collier P, Watson CJ, Voon V, Phelan D, Jan A, Mak G, Martos R, Baugh JA, Ledwidge MT and McDonald KM: Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur J Heart Fail. 13:1087–1095. 2011.PubMed/NCBI View Article : Google Scholar
25	Morishita T, Uzui H, Mitsuke Y, Amaya N, Kaseno K, Ishida K, Fukuoka Y, Ikeda H, Tama N and Yamazaki T: Association between matrix metalloproteinase-9 and worsening heart failure events in patients with chronic heart failure. ESC Heart Fail. 4:321–330. 2017.PubMed/NCBI View Article : Google Scholar
26	Lee SD, Chen LM, Kuo WW, Shu WT, Kuo WH, Huang EJ, Tsai CC, Li PC, Liu JY, Chen TH and Huang CY: Serum insulin-like growth factor-axis and matrix metalloproteinases in patients with rheumatic arthritis or rheumatic heart disease. Clin Chim Acta. 367:62–68. 2006.PubMed/NCBI View Article : Google Scholar
27	Kantor PF and Rusconi P: Biomarkers in pediatric heart failure: Their role in diagnosis and evaluating disease progression. Prog Pediatr Cardiol. 31:53–57. 2011.
28	de Couto G, Ouzounian M and Liu PP: Early detection of myocardial dysfunction and heart failure. Nat Rev Cardiol. 7:334–44. 2010.PubMed/NCBI View Article : Google Scholar
29	Yan AT, Yan RT, Spinale FG, Afzal R, Gunasinghe HR, Arnold M, Demers C, McKelvie RS and Liu PP: Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. J Card Fail. 12:514–519. 2006.PubMed/NCBI View Article : Google Scholar
30	Yoshihisa A, Sato Y, Kanno Y, Takiguchi M, Yokokawa T, Abe S, Misaka T, Sato T, Oikawa M, Kobayashi A, et al: Prognostic impacts of changes in left ventricular ejection fraction in heart failure patients with preserved left ventricular ejection fraction. Open Heart. 7(e001112)2020.PubMed/NCBI View Article : Google Scholar